Questcor Announces the Commercial Availability of Doral(R) and Outlines Future Development Pipeline

Questcor Pharmaceuticals, Inc. (AMEX:QSC) announcedtoday that it began to ship its new CNS product, Doral(R) (quazepam),a non-narcotic, selective benzodiazepine receptor agonist that isindicated for the treatment of insomnia, characterized by difficultyin falling asleep, frequent nocturnal awakenings, and/or early morningawakenings. The first sales to wholesalers were recorded at the end ofMay and Questcor's national sales force will begin detailing theproduct in the third quarter. James Fares, Questcor's President andCEO, commented, "We are pleased to have completed the process ofconverting Doral into a Questcor product and reintroducing it to themarket less than a month after we acquired it. We look forward toworking with the neurology community to help them understand the manyattributes of this important product. We are also excited about oursales force promoting both Acthar Gel(R) (repository corticotropininjection) and Doral during their visits with professionals in theneurology community."

Pipeline Update

Mr. Fares also commented on Questcor's goal to build a high value,low risk pipeline of medically important CNS products. "With thestrong success we are seeing from our efforts to grow Acthar Gel, weare ready to turn to the next stage of our evolution into a leadingCNS focused specialty pharmaceutical company, the building of ourdevelopment pipeline. We recognize that a high quality pipeline isessential to the success of any pharmaceutical company and we are hardat work evaluating a number of opportunities to begin to build a CNSpipeline that would provide us with significant future opportunity.These programs will focus on the CNS market, fit our capitalstructure, and have a low regulatory risk."

Questcor has filed a shelf registration statement on Form S-3 withthe Securities and Exchange Commission. When declared effective by theSEC, the shelf registration statement will enable the Company to offerand sell up to $25 million of common shares or debt securities fromtime to time in one or more offerings. The terms of any such futureoffering would be established at the time of such offering. Questcorintends to use the proceeds from such offerings to build a pipeline ofmedically important CNS products as described above.

A registration statement relating to these securities has beenfiled with the Securities and Exchange Commission but has not yetbecome effective. These securities may not be sold nor may offers tobuy be accepted prior to the time the registration statement becomeseffective. This press release shall not constitute an offer to sell orthe solicitation of an offer to buy, nor shall there be any sale ofthese securities in any jurisdiction in which such offer,solicitation, or sale would be unlawful prior to registration orqualification under the securities laws of any such jurisdiction. Anyoffer of these securities will be made solely by means of theprospectus included in the registration statement and any prospectussupplement that may be issued in respect of any such offering. Awritten prospectus, when available, meeting the requirements ofSection 10 of the Securities Act of 1933, may be obtained bycontacting Patricia Everest, Questcor Pharmaceuticals, Inc., 3260Whipple Road, Union City, CA 94587.

About Questcor -- Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) isa specialty pharmaceutical company that develops and commercializesnovel therapeutics for the treatment of neurological disorders.Questcor currently markets H.P. Acthar(R) Gel (repositorycorticotropin injection), an injectable drug indicated for thetreatment of exacerbations associated with Multiple Sclerosis andDoral(R) (quazepam) that is indicated for the treatment of insomnia,characterized by difficulty in falling asleep, frequent nocturnalawakenings, and/or early morning awakenings. For more information,please visit www.questcor.com.

Note: Except for the historical information contained herein, thispress release contains forward-looking statements that involve risksand uncertainties. Such statements are subject to certain factors,which may cause Questcor's results to differ from those reportedherein. Factors that may cause such differences include, but are notlimited to, Questcor's ability to accurately forecast and create thedemand for its products, the gross margin achieved from the sale ofits products, Questcor's ability to enforce its product returnspolicy, the accuracy of the prescription data purchased fromindependent third parties by Questcor, the sell-through by Questcor'sdistributors, the inventories carried by Questcor's distributors, andthe expenses and other cash needs for the upcoming periods, Questcor'sability to obtain finished goods from its sole source contractmanufacturers on a timely basis if at all, Questcor's potential futureneed for additional funding, Questcor's ability to utilize its netoperating loss carry forwards to reduce income taxes on the sale ofits products, uncertainties regarding Questcor's intellectual propertyand other research, development, marketing and regulatory risks, andto the ability of Questcor to implement its strategy and acquireproducts and, if acquired, to market them successfully as well as therisks discussed in Questcor's annual report on Form 10-K for the yearended December 31, 2005 and other documents filed with the Securitiesand Exchange Commission. The risk factors and other informationcontained in these documents should be considered in evaluatingQuestcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the resultof any revisions to these forward-looking statements, which may bemade to reflect events or circumstances after the date hereof or toreflect the occurrence of unanticipated events.